Portola Pharmaceuticals Inc  

(Public, NASDAQ:PTLA)   Watch this stock  
Find more results forPTLA
18.91
+0.33 (1.78%)
Real-time:   2:50pm GMT-5
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.18 - 18.92
52 week 15.68 - 52.89
Open 18.69
Vol / Avg. 303,888.00/871,733.00
Mkt cap 1,107.39M
P/E     -
Div/yield     -
EPS -5.04
Shares 56.54M
Beta 1.14
Inst. own 93%
Feb 24, 2017
Q4 2016 Portola Pharmaceuticals Inc Earnings Release (Estimated) - 4:00pm GMT-5 - Add to calendar
Nov 8, 2016
Portola Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 7, 2016
Q3 2016 Portola Pharmaceuticals Inc Earnings Call - Webcast
Nov 7, 2016
Q3 2016 Portola Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -976.57% -1876.60%
Operating margin -980.94% -1882.15%
EBITD margin - -1871.28%
Return on average assets -100.73% -49.27%
Return on average equity -133.66% -58.44%
Employees 137 -
CDP Score - -

Address

270 East Grand Avenue, Suite 22
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2446864 (Phone)
+1-650-2467376 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Officers and directors

Charles J. Homcy M.D. Co-Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Hollings C. Renton III Independent Co-Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
William Lis Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mardi C. Dier Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John T. Curnutte M.D. Ph.D. Executive Vice President - Research & Development
Age: 63
Bio & Compensation  - Reuters
Tao Fu Executive Vice President, Chief Commercial and Business officer
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 58
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Director
Age: 64
Bio & Compensation  - Reuters
John H. Johnson Director
Age: 57
Bio & Compensation  - Reuters
David Carter Stump M.D. Director
Age: 66
Bio & Compensation  - Reuters